(18)F-fluoromisonidazole Positron Emission Tomography Can Predict Pathological Necrosis of Brain Tumors

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2016 Feb 5

PMID 26841941

Citations 12

Authors

Takuya Toyonaga

Kenji Hirata

Shigeru Yamaguchi

Kanako C Hatanaka

Sayaka Yuzawa

Osamu Manabe

Kentaro Kobayashi

Shiro Watanabe

Tohru Shiga

Shunsuke Terasaka

Hiroyuki Kobayashi

Yuji Kuge

Nagara Tamaki

Affiliations

Soon will be listed here.

Abstract

Purpose: Tumor necrosis is one of the indicators of tumor aggressiveness. (18)F-fluoromisonidazole (FMISO) is the most widely used positron emission tomography (PET) tracer to evaluate severe hypoxia in vivo. Because severe hypoxia causes necrosis, we hypothesized that intratumoral necrosis can be detected by FMISO PET in brain tumors regardless of their histopathology. We applied FMISO PET to various types of brain tumors before tumor resection and evaluated the correlation between histopathological necrosis and FMISO uptake.

Methods: This study included 59 brain tumor patients who underwent FMISO PET/computed tomography before any treatments. According to the pathological diagnosis, the brain tumors were divided into three groups: astrocytomas (group 1), neuroepithelial tumors except for astrocytomas (group 2), and others (group 3). Two experienced neuropathologists evaluated the presence of necrosis in consensus. FMISO uptake in the tumor was evaluated visually and semi-quantitatively using the tumor-to-normal cerebellum ratio (TNR).

Results: In visual analyses, 26/27 cases in the FMISO-positive group presented with necrosis, whereas 28/32 cases in the FMISO-negative group did not show necrosis. Mean TNRs with and without necrosis were 3.49 ± 0.97 and 1.43 ± 0.42 (p < 0.00001) in group 1, 2.91 ± 0.83 and 1.44 ± 0.20 (p < 0.005) in group 2, and 2.63 ± 1.16 and 1.35 ± 0.23 (p < 0.05) in group 3, respectively. Using a cut-off value of TNR = 1.67, which was calculated by normal reference regions of interest, we could predict necrosis with sensitivity, specificity, and accuracy of 96.7, 93.1, and 94.9 %, respectively.

Conclusions: FMISO uptake within the lesion indicated the presence of histological micro-necrosis. When we used a TNR of 1.67 as the cut-off value, intratumoral micro-necrosis was sufficiently predictable. Because the presence of necrosis implies a poor prognosis, our results suggest that FMISO PET could provide important information for treatment decisions or surgical strategies of any type of brain tumor.

Citing Articles

Identifying G6PC3 as a Potential Key Molecule in Hypoxic Glucose Metabolism of Glioblastoma Derived from the Depiction of F-Fluoromisonidazole and F-Fluorodeoxyglucose Positron Emission Tomography.

Okamoto M, Yamaguchi S, Sawaya R, Echizenya S, Ishi Y, Kaneko S Biomed Res Int. 2024; 2024:2973407.

PMID: 38449509 PMC: 10917478. DOI: 10.1155/2024/2973407.

Current landscape and future perspectives in preclinical MR and PET imaging of brain metastasis.

Aasen S, Espedal H, Keunen O, Adamsen T, Bjerkvig R, Thorsen F Neurooncol Adv. 2022; 3(1):vdab151.

PMID: 34988446 PMC: 8704384. DOI: 10.1093/noajnl/vdab151.

Potential novel imaging targets of inflammation in cardiac sarcoidosis.

Park J, Young B, Miller E J Nucl Cardiol. 2021; 29(5):2171-2187.

PMID: 34734365 DOI: 10.1007/s12350-021-02838-w.

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and F-FMISO PET.

Huang S, Michalek J, Reardon D, Wen P, Floyd J, Fox P Sci Rep. 2021; 11(1):7632.

PMID: 33828310 PMC: 8027395. DOI: 10.1038/s41598-021-84331-5.

Quantitative FDG PET Assessment for Oncology Therapy.

Hirata K, Tamaki N Cancers (Basel). 2021; 13(4).

PMID: 33669531 PMC: 7922629. DOI: 10.3390/cancers13040869.

References

Kobayashi K, Hirata K, Yamaguchi S, Manabe O, Terasaka S, Kobayashi H . Prognostic value of volume-based measurements on (11)C-methionine PET in glioma patients. Eur J Nucl Med Mol Imaging. 2015; 42(7):1071-80. DOI: 10.1007/s00259-015-3046-1. View

Koch C, Chapman J . Is misonidazole binding to mouse tissues a measure of cellular pO2?. Biochem Pharmacol. 1987; 36(20):3487-94. DOI: 10.1016/0006-2952(87)90330-3. View

Szeto M, Chakraborty G, Hadley J, Rockne R, Muzi M, Alvord Jr E . Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 2009; 69(10):4502-9. PMC: 3760276. DOI: 10.1158/0008-5472.CAN-08-3884. View

Okamoto S, Shiga T, Yasuda K, Ito Y, Magota K, Kasai K . High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med. 2013; 54(2):201-7. DOI: 10.2967/jnumed.112.109330. View

Bentzen L, Keiding S, Horsman M, Gronroos T, Hansen S, Overgaard J . Assessment of hypoxia in experimental mice tumours by [18F]fluoromisonidazole PET and pO2 electrode measurements. Influence of tumour volume and carbogen breathing. Acta Oncol. 2002; 41(3):304-12. DOI: 10.1080/02841860260088863. View

Wahl R, Jacene H, Kasamon Y, Lodge M . From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50 Suppl 1:122S-50S. PMC: 2755245. DOI: 10.2967/jnumed.108.057307. View

Rasey J, Nelson N, Chin L, Evans M, Grunbaum Z . Characteristics of the binding of labeled fluoromisonidazole in cells in vitro. Radiat Res. 1990; 122(3):301-8. View

Hirata K, Terasaka S, Shiga T, Hattori N, Magota K, Kobayashi H . ¹⁸F-Fluoromisonidazole positron emission tomography may differentiate glioblastoma multiforme from less malignant gliomas. Eur J Nucl Med Mol Imaging. 2012; 39(5):760-70. DOI: 10.1007/s00259-011-2037-0. View

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

10.

Swanson K, Chakraborty G, Wang C, Rockne R, Harpold H, Muzi M . Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 2008; 50(1):36-44. PMC: 4154624. DOI: 10.2967/jnumed.108.055467. View

11.

Miller C, Dunham C, Scheithauer B, Perry A . Significance of necrosis in grading of oligodendroglial neoplasms: a clinicopathologic and genetic study of newly diagnosed high-grade gliomas. J Clin Oncol. 2006; 24(34):5419-26. DOI: 10.1200/JCO.2006.08.1497. View

12.

Kawai N, Lin W, Cao W, Ogawa D, Miyake K, Haba R . Correlation between ¹⁸F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014; 41(10):1870-8. DOI: 10.1007/s00259-014-2776-9. View

13.

Bell C, Dowson N, Fay M, Thomas P, Puttick S, Gal Y . Hypoxia imaging in gliomas with 18F-fluoromisonidazole PET: toward clinical translation. Semin Nucl Med. 2015; 45(2):136-50. DOI: 10.1053/j.semnuclmed.2014.10.001. View

14.

Piert M, Machulla H, Becker G, Aldinger P, Winter E, Bares R . Dependency of the [18F]fluoromisonidazole uptake on oxygen delivery and tissue oxygenation in the porcine liver. Nucl Med Biol. 2001; 27(8):693-700. DOI: 10.1016/s0969-8051(00)00151-7. View

15.

Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez J . pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011; 12:77. PMC: 3068975. DOI: 10.1186/1471-2105-12-77. View

16.

JENKINS W, Evans S, Koch C . Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. Int J Radiat Oncol Biol Phys. 2000; 46(4):1005-17. DOI: 10.1016/s0360-3016(99)00342-9. View

17.

Piert M, Machulla H, Becker G, Stahlschmidt A, Patt M, Aldinger P . Introducing fluorine-18 fluoromisonidazole positron emission tomography for the localisation and quantification of pig liver hypoxia. Eur J Nucl Med. 1999; 26(2):95-109. DOI: 10.1007/s002590050365. View

18.

Urtasun R, Band P, Chapman J, Feldstein M, Mielke B, Fryer C . Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med. 1976; 294(25):1364-7. DOI: 10.1056/NEJM197606172942503. View

19.

Spence A, Muzi M, Swanson K, OSullivan F, Rockhill J, Rajendran J . Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008; 14(9):2623-30. PMC: 4415875. DOI: 10.1158/1078-0432.CCR-07-4995. View

20.

Moradi A, Semnani V, Djam H, Tajodini A, Zali A, Ghaemi K . Pathodiagnostic parameters for meningioma grading. J Clin Neurosci. 2008; 15(12):1370-5. DOI: 10.1016/j.jocn.2007.12.005. View